

ENTITLEMENT OFFER & ACCEPTANCE FORM – DELAYS IN MAIL

Some postal delays experienced – Shareholders can contact Registry if accepting Offer

Adelaide, Australia, 5 May 2020: Australian high-tech company Micro-X Ltd (ASX: MX1) (**Micro-X** or the **Company**) a leader in cold cathode x-ray technology for health and security markets globally, confirms that on 24 April 2020 it dispatched to eligible shareholders the Prospectus and accompanying Entitlement and Acceptance Forms for the underwritten Non-Renounceable Entitlement Offer (the **Entitlement Offer**).

Micro-X has been made aware that there has been some recent delays in receipt of the Prospectus and Entitlement Offer by mail due to restrictions relating to the COVID-19 pandemic. In light of this, it is recommended that shareholders note that additional time should be allowed if sending the Entitlement and Acceptance Forms back by post. The Entitlement Offer closes at 5.00pm (ACST) on Wednesday 6 May 2020.

Contacting the Registry if Experiencing Delays with Mail

For any eligible shareholder that may not have received their personalised Entitlement Offer or anticipates potential delays in accepting by mail prior to the closing date, please contact the share registry Computershare who can arrange to email the personalised Entitlement and Acceptance Form to you:

Telephone (within Australia): 1300 850 505
Telephone (outside Australia): +61 3 9415 4000
Website: www.investorcentre.com/contact

Authorised by the board of Micro-X.

– ENDS –

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for the global health and security markets, based on proprietary cold cathode, carbon nanotube emitter technology. The electronic control of emitters with this technology enables X-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. The Company has its core R&D, engineering and production capability at its facility in Adelaide, Australia.

The Company's first product, the *Carestream DRX Revolution Nano*, is an ultra-lightweight digital medical x-ray system for the rapidly expanding mobile x-ray market in hospitals and healthcare. The *Carestream DRX Revolution Nano* holds 510(k) and CE Mark certifications and is sold commercially in a number of global markets by the Company's exclusive distributor, Carestream Health, Inc. The Company has a portfolio of innovative products in development, aimed at customer solutions where there is little or no competition. This includes the Mobile Backscatter Imager or MBI which will image Improvised Explosive Devices for airport security, defence and counter-terrorism applications. The MBI is being jointly developed in partnership with Thales, a global supplier of defence and security technology systems, who are providing technical support and \$10 million of funding.

CONTACTS

Micro-X Limited	Investor Enquiries
Peter Rowland Managing Director Tel: +61 8 7099 3966 E: admin@micro-x.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com